ArticleWorld journal of gastrointestinal oncology2025
Investigation of gastrointestinal tumor symptoms and risk factors in eighty patients with Parkinson's disease.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is often accompanied by gastrointestinal symptoms; however, the relationship between PD and gastrointestinal tumors remains unclear.
aimTo explore the symptom characteristics and risk factors of gastrointestinal tumors in patients with PD by integrating clinical, neurological, gastrointestinal, and laboratory assessments.
methodsEighty patients with PD who were admitted to our hospital between January 2023 and December 2024 were retrospectively analyzed. Clinical characteristics and neurological status were evaluated using standardized scales, including the Mini-Mental State Examination, Depression Anxiety Stress Scale-21, Pittsburgh Sleep Quality Index Barthel Index, Non-Motor Symptoms Scale, and the Intake, Feeling nauseated, Emesis, physical Exam, Duration of symptoms (I-FEED) gastrointestinal dysfunction score. Laboratory indicators including tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4)] were measured. Differences between PD patients with and without gastrointestinal tumors were compared, and logistic regression was used to identify associated factors.
resultsAmong the 80 PD patients, 16 (20.00%) had gastrointestinal tumors. The most common symptoms in the tumor group were constipation (93.75%), urgency of defecation (75.00%), and abdominal tightness (75.00%). Patients with gastrointestinal tumors had significantly higher I-FEED, CEA, CA19-9, and CA72-4 levels (
conclusionThis study uniquely combines neurological symptom scales and tumor markers to evaluate gastrointestinal tumor risk in patients with PD. The findings suggest that gastrointestinal dysfunction and tumor marker elevation are key clinical indicators, and highlight the importance of comprehensive assessment in identifying high-risk PD patients for timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.